MedTrace Logo

Results From a Mexican Acute Promyelocytic Leukemia.

NCT04562818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2020-09-24

No results posted yet for this study

Summary

Retrospective, observational study, comparing treatments of acute promyelocytic leukemia in different centers in México.

There is no sufficient information about acute promyelocytic leukemia in America Latina, particularly in Mexico.

For these reason the investigators started a study adding all promyelocityc patients from the main Hospital in Mexico in order to put together a group of patient and analyze the response, overall survival and what are the characteristics of the population.

The investigators included 5 Hospital in Mexico City and states as Monterrey, Guadalajara, San Luis Potosi, Puebla, Veracruz, Yucatán, Oaxaca, Guanajuato, Estado de México.

Even do, the investigators didn´t have arsenic trioxide they are treating patients with standard chemotherapy. These paper will help to show the authorities that the cost of treating patient with standard chemotherapy is much more higher than ATO-ATRA. The investigators are now doing a cost benefit analysis so the investigators, can soon have ATO treatment as standard of care in Mexico for the treatment of acute promyelocytic leukemia.

Conditions

  • Promyelocytic Leukemia, Acute

Interventions

DIAGNOSTIC_TEST

Diagnosis

Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)

DIAGNOSTIC_TEST

Molecular and Karyotype

To realize the need of having more center we the technology to perform all of these tests

DIAGNOSTIC_TEST

Leucocytes

Sponsors & Collaborators

  • Instituto Nacional de Cancerologia de Mexico

    lead OTHER

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2017-01-31
Completion
2018-01-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562818 on ClinicalTrials.gov